Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new one-year results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir, the company's investigational, long-acting HIV-1 capsid inhibitor, in heavily treatment-experienced people living with multi-drug resistant HIV. The findings demonstrated that lenacapavir, administered subcutaneously every six months in combination with other antiretrovirals, achieved high rates of virologic suppression

New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor

Hookipa Pharma Inc

Hookipa Pharma Inc (NASDAQ: HOOK) amended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ: GILD) for arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV). In April 2018, Gilead licensed exclusive rights to Hookipa's arenaviral platform to develop immunotherapies for HIV and hepatitis B virus (HBV).

Hookipa Pharma Stock Surges On HIV Pact With Gilead

Why are investors unenthused with the biotech giant's earnings report?

Inside Gilead's Lackluster $7.2 Billion Q4 Earnings

Novavax

Vertex Pharmaceuticals

Their long-term prospects appear to be bright.

3 Biotech Stocks to Buy in February

How will the cost of a settlement affect Gilead's profits over the foreseeable future?

Tracking Gilead's 4 Big Stories and a Lawsuit in 2022

Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.

Gilead (GILD) Veklury Retains Activity Against Omicron Variant

Gilead Sciences Inc (NASDAQ: GILD) announced new data from an interim analysis of its ongoing, Phase 2/3 study of Veklury (remdesivir) in pediatric patients hospitalized with COVID-19. The data will be presented at the 29th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2022).

Gilead Shares Updated Data From Remdesivir Study In Pediatric COVID-19 Patients

If Gilead has bad news on magrolimab, it could ripple throughout the industry.

Is the FDA's Partial Hold Bad News for Gilead Investors?

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from an interim analysis of its ongoing, Phase 2/3 single arm, open-label study to evaluate the safety, tolerability and pharmacokinetics of Veklury® (remdesivir) in pediatric patients hospitalized with COVID-19 with ages ranging from 28 days to less than 18 years. This data will be presented at the 29th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2022) taking place from

Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of cumulative 5-year results from two Phase 3 studies (Study 1489 and Study 1490) of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF). The new, long-term data further demonstrate the sustained efficacy and safety profile and lack of treatment failure due to resistance in the final resistance analysis population associated with Biktarvy for th

Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults

Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) has demonstrated in vitro activity against ten SARS-CoV-2 variants, including omicron.  The study results showed similar activity of Veklury against the variants, and an early ancestral A lineage isolate detected in Seattle, WA (WA1 strain).

Gilead's Remdesivir Retains Antiviral Activity Against Several COVID-19 Variants, Including Omicron

There are some reasons to be optimistic about this drugmaker.

2 Green Flags For Gilead Sciences' Future

Shares of Gilead Sciences Inc. GILD, -2.51% gained 0.6% in premarket trading on Friday after the company said Veklury, its COVID-19 drug, demonstrated in-vitro activity against omicron and 9 other variants. The research, which was announced in a news release on Friday morning, was published Thursday as a preprint.

Gilead says in-vitro study shows its COVID-19 drug Veklury is active against omicron

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today released data demonstrating the in vitro activity of Veklury® (remdesivir) against ten SARS-CoV-2 variants, including Omicron. Results of Gilead studies are consistent with other in vitro studies independently conducted by researchers from institutions in other countries, including Belgium, Czech Republic, Germany, Poland, and the United States, which confirmed Veklury's antiviral activity against multiple previous

Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies

Both offer yields more than twice what the S&P 500 provides.

2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows

AllianceBernstein Hld

Cheniere Energy Partners

LyondellBasell Industries

OneMain Hld

Southern Copper

Western Union

These dividend stocks, including SCCO stock and CQP stock, offer high yields, a proven track record and high ratings in Dividend Grader. The post The 7 Highest Dividend Stocks for Income Investors appeared first on InvestorPlace.

The 7 Highest Dividend Stocks for Income Investors

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new data from the company's HIV and COVID-19 research and development programs at the 29th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2022) taking place from February 12-16. The data reflect Gilead's enduring dedication to advancing global health through scientific innovation by addressing some of the world's most challenging viruses. Gilead's commit

Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs

Gilead Sciences has seen a reasonable 2021, but the outlook for 2022 is a bit of a shock.

Gilead Sciences: The Science Does Not Add Up

Gilead Sciences, Inc. (NASDAQ: GILD) shares remain under pressure even though the company reported strong fourth-quarter results last trading week. Gilead has increased quarterly dividend Gilead Sciences is an American biopharmaceutical company that focuses on researching and developing antiviral drugs used to treat HIV, hepatitis B, hepatitis C, and influenza.

Should I buy Gilead Sciences shares after strong Q4 results?

Gilead released FY21 earnings on Feb. 1 - revenues grew by 11% to $27bn and the P/E ratio was ~9x - likely to be best in the big Pharma sector. FY22 guidance is for a fall in revenues, but COVID therapy Veklury could bolster sales after an approval in a non-hospitalised setting.

Gilead Sciences Stock: Look Beyond Mediocre 2022 Guidance - Pharma Can Deliver When It Matters

Gilead's success could be inversely proportional to Pfizer's success with its COVID-19 pill.

How Big Are Gilead's Latest COVID Wins?

GlaxoSmithKline

GlaxoSmithKline plc GSK has settled a patent dispute between ViiV Healthcare and Gilead Sciences Inc GILD. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

GSK To Get $1.25B As Settlement For HIV Treatment Drug Patent Row With Gilead

Gilead (GILD) misses on earnings but beats on sales in the fourth quarter. While the HIV business maintains momentum on Biktarvy, sales of Veklury decline.

Gilead (GILD) Q4 Earnings Miss on Legal Settlement Charges

Gilead Sciences Inc GILD posted Q4 FY21 adjusted EPS of $0.69, sharply below $2.19 posted a year ago. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates

Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q4 2021 Results - Earnings Call Transcript

News for Gilead Sciences Stock (GILD)